MDLive

About MDLive

MDLIVE is one of the longest-running telehealth platforms in the United States, founded in 2009 and now operating as part of Cigna’s Evernorth Health Services division. The platform offers brand-name anti-obesity medications including Wegovy and Zepbound, with monthly costs ranging from $99-$299. MDLIVE’s corporate backing and 15+ year track record give it institutional credibility that standalone telehealth startups cannot replicate, and its integration with Cigna’s insurance network provides potential cost advantages for patients within that ecosystem.

Trust metrics for MDLIVE are polarized. On Trustpilot, the platform has a 1.5 rating across 12,130+ reviews, one of the lowest scores in our coverage at extremely high volume. The company also holds an F rating with the BBB. These numbers require context: MDLIVE serves millions of patients across dozens of medical specialties, and Trustpilot reviews skew toward patients with negative experiences across all service lines — not just weight management. Still, the data cannot be ignored, and prospective GLP-1 patients should understand that the broader MDLIVE experience has generated significant consumer frustration.

Clinically, MDLIVE offers a high-support model for its weight management program. Patients have access to dietitian consultations, structured treatment protocols, and the medical oversight you would expect from a Cigna-affiliated platform. The focus on brand-name FDA-approved medications means patients receive Wegovy, Zepbound, and other clinically validated anti-obesity drugs rather than compounded alternatives. Lab testing availability varies by plan and location, which is less consistent than competitors that include labs as standard.

The Cigna/Evernorth affiliation is MDLIVE’s most significant advantage. Patients with Cigna insurance may access GLP-1 prescriptions at substantially reduced costs, and the platform’s integration with pharmacy benefit managers can streamline prior authorization processes that frustrate patients at independent providers. For patients already within the Cigna network, MDLIVE can serve as a seamless extension of their existing healthcare, with medical records and treatment history accessible to their broader care team.

The challenge with MDLIVE is reconciling its institutional strengths with its consumer satisfaction record. The platform operates at massive scale, and that scale introduces variability in provider quality, wait times, and customer service responsiveness. Patients who thrive with MDLIVE tend to be those who value insurance integration and brand-name medications over personalized attention. Those seeking a boutique, high-touch telehealth experience will likely find the MDLIVE experience impersonal by comparison.

MDLive GLP-1 Medications

At a Glance